SRSF2 and Thrombocytopenia: On the other hand, in univariate analysis, leukemia-free survival was not influenced by driver mutation status, ASXL1/SRSF2 mutations, unfavorable karyotype, leukocyte count >25 × 109/l, peripheral blasts ≥1%, hemoglobin <10 g/dl, or thrombocytopenia <100 × 109/l (p > 0.1) (Table 2).